FDA OKs Stem Cell Therapy to Reduce Infection Risk

The agency called the approval of omidubicel "an important advance" for patients with blood cancer who are undergoing allogeneic umbilical cord blood stem cell transplants.
FDA Approvals

source https://www.medscape.com/viewarticle/990896?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?